Fig. 4
From: Deciphering MOSPD1’s impact on breast cancer progression and therapeutic response
Analysis of the correlation between MOSPD1 expression levels and prognosis in BC. Note(A-B) Kaplan-Meier survival curves for BC patients with high and low MOSPD1 expression: (A) Overall survival rate; (B) Progression-free survival period. (C-D) Subgroup analysis based on HER2 status: (C) Overall survival rate in HER2-negative patients; (D) Overall survival rate in HER2-positive patients. (E-F) Association of MOSPD1 expression levels with prognosis in BC: (E) Univariate Cox regression analysis results; (F) Multivariate Cox regression analysis results. (G-H) Prediction of prognosis in BC patients combining MOSPD1 expression with other clinical variables: (G) Predicted 1-year, 3-year, and 5-year overall survival rates using the risk scoring model; (H) Calibration curve of the model verifying prediction accuracy